Drug intelligence / Profile preview

midazolam + glycopyrrolate + ketamine + propofol

Development stage: Preclinical
Lead developer: Melt Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of four medications used for procedural sedation and analgesia. This multimodal approach combines the sedative effects of midazolam and propofol with the analgesic properties of ketamine, while glycopyrrolate helps counter ketamine-induced hypersalivation. The combination allows for lower doses of each individual component, potentially reducing dose-related side effects while maintaining effective sedation and analgesia.

Targets

GABRR (GABA-A receptor subunit rho)mAChR (Muscarinic acetylcholine receptors)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on midazolam + glycopyrrolate + ketamine + propofol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on midazolam + glycopyrrolate + ketamine + propofol.

Explore the full profile